Truveta data shows Zepbound prescriptions in older adults up about 72% since June, while younger age groups held roughly flat over the same stretch.
Recap by typeshit. Full story at Truveta.
New generics and steady prices drove the jump in sales value, with Eli Lilly's tirzepatide leading the market.
UBS says volumes grew about 55% while net prices fell roughly 14%, and points to about 500,000 people joining Lilly's Medicare bridge program in a few months.
A new market report values the sector at $97.5 billion in 2025 and expects oral and multi-pathway drugs to grow fastest as Medicare coverage starts in mid-2026.
Forbes compares what brand-name semaglutide and tirzepatide cost against compounded GLP-1 versions.
Reuters reported the approval as Novo shares sit down 13% this year. STEP Young data in kids aged 6 to 11 is due at ObesityWeek in November.
A woman with four triglyceride-driven pancreatitis episodes came off insulin and had none for 12 months. The authors stress it shows association, not cause.
Loading…